{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T19:04:31Z","timestamp":1792177471800,"version":"4.4.0"},"reference-count":61,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T00:00:00Z","timestamp":1729641600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Breast cancer is the most common cancer among women worldwide, and its incidence rate is still increasing, especially among younger women. Nationally, it constitutes one-fifth of all cancer cases and almost 40% of all female cancers. With a median age of 51 years, breast cancer is diagnosed at least a decade earlier, and at more advanced stages compared to Western societies. Hereditary cancers account for 10% or more of all cancer burden worldwide. With expanded indications, increased number of genes tested, and significant decline in cost of testing, such proportion will probably increase. Individuals with pathogenic variants of <jats:italic>BRCA1<\/jats:italic> and <jats:italic>BRCA2<\/jats:italic> are at higher risk of breast, ovarian, pancreatic and many other cancers. Over the past two decades, several highly penetrant cancer-susceptibility genes were identified across almost all tumor sites, thus increasing the need for comprehensive cancer genetic programs that address the testing process, counselling patients and at-risk family members, and then deal with all testing results and its consequences. In addition to its important role in preventing more cancers in index patients themselves and among their close relatives, identification of pathogenic or likely pathogenic variants, mostly in <jats:italic>BRCA1<\/jats:italic> or <jats:italic>BRCA2<\/jats:italic>, may inform therapeutic decisions in common cancers including breast, ovarian, prostate and pancreatic cancers. In this manuscript, we describe the experience of a comprehensive cancer center, in a resource-limited country in establishing a comprehensive clinical cancer genetics program that can serve as an example for others who share similar demographic and financial restrains.<\/jats:p>","DOI":"10.3389\/fonc.2024.1431985","type":"journal-article","created":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T05:11:02Z","timestamp":1729660262000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Establishment of a clinical cancer genetics program for breast cancer in a resource-limited country; challenges and opportunities"],"prefix":"10.3389","volume":"14","author":[{"given":"Hikmat","family":"Abdel-Razeq","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baha","family":"Sharaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faris","family":"Tamimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hira Bani","family":"Hani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osama","family":"Alsmadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanan","family":"Khalil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"Abunasser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Edaily","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asem","family":"Mansour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,10,23]]},"reference":[{"key":"B1","unstructured":"About Jordan\n          \n          UNFPA Jordan\n          \n          2016"},{"key":"B2","unstructured":"Jordan | Economic indicators\n          \n          Moody\u2019s analytics"},{"key":"B3","unstructured":"Unemployment rate for Jordanians (Q4, 2023)\n          \n          Department of Statistics"},{"key":"B4","unstructured":"World bank open data"},{"key":"B5","unstructured":"King Hussein Cancer Center"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1200\/GO.20.00141","article-title":"Oncology medical training and practice: Managing Jordan\u2019s brain drain through brain train-The King Hussein Cancer Center experience","volume":"6","author":"Abdel-Razeq","year":"2020","journal-title":"JCO Glob Oncol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B9","unstructured":"Cancer incidence in Jordan\n          \n          \n          Non-Communicable Diseases Directorate Ministry of Health, Jordan\n          \n          2015"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70165-7","article-title":"Breast cancer in Arab populations: molecular characteristics and disease management implications","volume":"14","author":"Chouchane","year":"2013","journal-title":"Lancet Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15225398","article-title":"Breast cancer in the Arabian gulf countries","volume":"15","author":"Al-Shamsi","year":"2023","journal-title":"Cancers"},{"key":"B12","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1056\/NEJM200007133430201","article-title":"Environmental and heritable factors in the causation of cancer \u2014 Analyses of cohorts of twins from Sweden, Denmark, and Finland","volume":"343","author":"Lichtenstein","year":"2000","journal-title":"N Engl J Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1126\/science.1251827","article-title":"Two decades after BRCA: Setting paradigms in personalized cancer care and prevention","volume":"343","author":"Couch","year":"2014","journal-title":"Science"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.01854","article-title":"Genetic testing and results in a population-based cohort of breast cancer patients and ovarian cancer patients","volume":"37","author":"Kurian","year":"2019","journal-title":"J Clin Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2012.123","article-title":"Cancer treatment according to BRCA1 and BRCA2 mutations","volume":"9","author":"Maxwell","year":"2012","journal-title":"Nat Rev Clin Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/ejhg.2016.93","article-title":"The biological effects and clinical implications of BRCA mutations: where do we go from here","volume":"24","author":"Stoppa-Lyonnet","year":"2016","journal-title":"Eur J Hum Genet"},{"key":"B17","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1001\/jama.2017.7112","article-title":"Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers","volume":"317","author":"Kuchenbaecker","year":"2017","journal-title":"JAMA"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.6772","article-title":"Characterization of BRCA1 and BRCA2 mutations in a large United States sample","volume":"24","author":"Chen","year":"2006","journal-title":"J Clin Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djt095","article-title":"Cancer risks for BRCA1 and BRCA2 mutation carriers, results from prospective analysis of EMBRACE","volume":"105","author":"Mavaddat","year":"2013","journal-title":"J Natl Cancer Inst"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.1066","article-title":"Meta-analysis of BRCA1 and BRCA2 penetrance","volume":"25","author":"Chen","year":"2007","journal-title":"J Clin Oncol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1186\/s12885-018-4079-1","article-title":"Germline BRCA1\/BRCA2 mutations among high risk breast cancer patients in Jordan","volume":"18","author":"Abdel-Razeq","year":"2018","journal-title":"BMC Cancer"},{"key":"B22","unstructured":"Breast, ovarian and pancreatic cancer. Genetic\/familial high risk assessment"},{"key":"B23","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1200\/JCO.23.02225","article-title":"Germline testing in patients with breast cancer: ASCO-Society of Surgical Oncology Guideline","volume":"42","author":"Bedrosian","year":"2024","journal-title":"J Clin Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1200\/OP.23.00771","article-title":"Germline testing in patients with breast cancer: ASCO-Society of Surgical Oncology Guideline Q and A","volume":"20","author":"Kurian","year":"2024","journal-title":"JCO Oncol Pract"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1001\/jamaoncol.2019.3323","article-title":"A cost-effectiveness analysis of multigene testing for all patients with breast cancer","volume":"5","author":"Sun","year":"2019","journal-title":"JAMA Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.5694\/mja2.51906","article-title":"Universal genetic testing for women with newly diagnosed breast cancer in the context of multidisciplinary team care","volume":"218","author":"De Silva","year":"2023","journal-title":"Med J Aust"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-022-12595-w","article-title":"Integration of universal germline genetic testing for all new breast cancer patients","volume":"30","author":"Culver","year":"2023","journal-title":"Ann Surg Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-019-07549-8","article-title":"Consensus guidelines on genetic` testing for hereditary breast cancer from the American society of breast surgeons","volume":"26","author":"Manahan","year":"2019","journal-title":"Ann Surg Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.673094","article-title":"rates of variants of uncertain significance among patients with breast cancer undergoing genetic testing: regional perspectives","volume":"12","author":"Abdel-Razeq","year":"2022","journal-title":"Front Oncol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/BCTT.S394092","article-title":"Guideline-based, Multi-gene panel germline genetic testing for at-risk patients with breast cancer","volume":"15","author":"Abdel-Razeq","year":"2023","journal-title":"Breast Cancer (Dove Med Press)"},{"key":"B31","doi-asserted-by":"publisher","first-page":"14906","DOI":"10.1038\/s41598-021-94403-1","article-title":"Prevalence and predictors of germline BRCA1 and BRCA2 mutations among young patients with breast cancer in Jordan","volume":"11","author":"Abdel-Razeq","year":"2021","journal-title":"Sci Rep"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.10591","article-title":"Implementation of universal pan-cancer germline genetic testing in an Arab population: The Jordanian exploratory cancer genetics (Jo-ECAG) study","volume":"41","author":"Abdel-Razeq","year":"2023","journal-title":"JCO"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2023.1194075","article-title":"Pathogenic germline variants in patients with breast cancer: conversations across generations, practices and patients\u2019 attitude","volume":"14","author":"Abdel-Razeq","year":"2023","journal-title":"Front Genet"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/S1471-4914(02)02434-6","article-title":"The relationship between the roles of BRCA genes in DNA repair and cancer predisposition","volume":"8","author":"Tutt","year":"2002","journal-title":"Trends Mol Med"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4292","article-title":"HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures","volume":"23","author":"Davies","year":"2017","journal-title":"Nat Med"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/nature03445","article-title":"Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy","volume":"434","author":"Farmer","year":"2005","journal-title":"Nature"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/nature03443","article-title":"Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase","volume":"434","author":"Bryant","year":"2005","journal-title":"Nature"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60892-6","article-title":"Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial","volume":"376","author":"Tutt","year":"2010","journal-title":"Lancet"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz012","article-title":"OlympiAD final overall survival and tolerability results: olaparib versus chemotherapy treatment of physician\u2019s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer","volume":"30","author":"Robson","year":"2019","journal-title":"Ann Oncol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1802905","article-title":"Talazoparib in patients with advanced breast cancer and a germline BRCA mutation","volume":"379","author":"Litton","year":"2018","journal-title":"N Engl J Med"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.08.2098","article-title":"Talazoparib versus chemotherapy in patients with germline BRCA1\/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial","volume":"31","author":"Litton","year":"2020","journal-title":"Ann Oncol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.18632\/aging.202152","article-title":"Comparative efficacy, safety, and acceptability of single-agent poly (ADP-ribose) polymerase (PARP) inhibitors in BRCA-mutated HER2-negative metastatic or advanced breast cancer: a network meta-analysis","volume":"13","author":"Wang","year":"2020","journal-title":"Aging"},{"key":"B43","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.annonc.2021.11.018","article-title":"Veliparib monotherapy following carboplatin\/paclitaxel plus veliparib combination therapy in patients with germline BRCA-associated advanced breast cancer: results of exploratory analyses from the phase III BROCADE3 trial","volume":"33","author":"Han","year":"2022","journal-title":"Ann Oncol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30447-2","article-title":"Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"21","author":"Di\u00e9ras","year":"2020","journal-title":"Lancet Oncol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.09.159","article-title":"Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1\/2 and high-risk, early breast cancer","volume":"33","author":"Geyer","year":"2022","journal-title":"Ann Oncol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2105215","article-title":"Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer","volume":"384","author":"Tutt","year":"2021","journal-title":"N Engl J Med"},{"key":"B47","unstructured":"Breast cancer. Version 2.2024"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsb1702054","article-title":"Advantages of a truly open-access data-sharing model","volume":"376","author":"Bertagnolli","year":"2017","journal-title":"N Engl J Med"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-022-06523-5","article-title":"Primary care physician referral practices regarding BRCA1\/2 genetic co unseling in a major health system","volume":"195","author":"Linfield","year":"2022","journal-title":"Breast Cancer Res Treat"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1001\/jama.292.12.1469","article-title":"The \u2018duty to warn\u2019 a patient\u2019s family members about hereditary disease risks","volume":"292","author":"Offit","year":"2004","journal-title":"JAMA"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1002\/mgg3.464","article-title":"Role of the general practitioner in the care of BRCA1 and BRCA2 mutation carriers: General practitioner and patient perspectives","volume":"6","author":"Vande Perre","year":"2018","journal-title":"Molec Gen Gen Med"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1007\/s13187-017-1226-3","article-title":"Women with family history of breast cancer: How much are they aware of their risk","volume":"33","author":"Seven","year":"2018","journal-title":"J Canc Educ"},{"key":"B53","doi-asserted-by":"publisher","first-page":"17573","DOI":"10.1038\/s41598-020-74250-2","article-title":"BRCA1 and BRCA2 genes mutations among high risk breast cancer patients in Jordan","volume":"10","author":"Abu-Helalah","year":"2020","journal-title":"Sci Rep"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-1465","article-title":"Effectiveness of prophylactic surgeries in BRCA1 or BRCA2 mutation carriers: a meta-analysis and systematic review","volume":"22","author":"Li","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.g226","article-title":"Contralateral mastectomy and survival after breast cancer in carriers of BRCA1 and BRCA2 mutations: retrospective analysis","volume":"348","author":"Metcalfe","year":"2014","journal-title":"BMJ"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1265197","article-title":"Surgical options for patients with early-stage breast cancer and pathogenic germline variants: an oncologist perspectives","volume":"13","author":"Abdel-Razeq","year":"2023","journal-title":"Front Oncol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"e7161","DOI":"10.5867\/medwave.2018.04.7160","article-title":"Prophylactic mastectomy versus surveillance for the prevention of breast cancer in women\u2019s BRCA carriers","volume":"18","author":"Honold","year":"2018","journal-title":"Medwave"},{"key":"B58","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1001\/jamasurg.2017.3422","article-title":"Oncologic safety of prophylactic nipple-sparing mastectomy in a population with BRCA mutations: a multi-institutional study","volume":"153","author":"Jakub","year":"2018","journal-title":"JAMA Surg"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djv033","article-title":"Breast cancer risk after salpingo-oophorectomy in healthy BRCA1\/2 mutation carriers: revisiting the evidence for risk reduction","volume":"107","author":"Heemskerk-Gerritsen","year":"2015","journal-title":"J Natl Cancer Inst"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2010.1237","article-title":"Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality","volume":"304","author":"Domchek","year":"2010","journal-title":"JAMA"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2022.02.019","article-title":"Risk-reducing salpingo-oophorectomy and breast cancer risk in BRCA1 or BRCA2 mutation carriers: A systematic review and meta-analysis","volume":"48","author":"Wang","year":"2022","journal-title":"Eur J Surg Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1431985\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T05:11:08Z","timestamp":1729660268000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1431985\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,23]]},"references-count":61,"alternative-id":["10.3389\/fonc.2024.1431985"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2024.1431985","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,23]]},"article-number":"1431985"}}